Base Editing Might Be Key to CAR T-cell Therapy.
Researchers used a unique base-editing strategy to engineer chimeric-antigen receptor (CAR) T cells that engraft in the host and remain invisible to remaining antibody drugs.
APA
(2026). Base Editing Might Be Key to CAR T-cell Therapy.. Cancer discovery, 16(3), OF1. https://doi.org/10.1158/2159-8290.CD-NW2026-0007
MLA
. "Base Editing Might Be Key to CAR T-cell Therapy.." Cancer discovery, vol. 16, no. 3, 2026, pp. OF1.
PMID
41575289
Abstract
Researchers used a unique base-editing strategy to engineer chimeric-antigen receptor (CAR) T cells that engraft in the host and remain invisible to remaining antibody drugs. Of the 11 patients with T-cell acute lymphoblastic leukemia who received these BE-CAR7 T cells, all had complete morphogenic remission after 28 days, 82% underwent stem-cell transplantation, and 64% remain in remission 3 to 36 months after treatment.
MeSH Terms
Humans; Immunotherapy, Adoptive; Receptors, Chimeric Antigen; Gene Editing; T-Lymphocytes; Receptors, Antigen, T-Cell